Author: Wang, Jian; Zhu, Li; Liu, Longgen; Yan, Xuebing; Xue, Leyang; Huang, Songping; Zhang, Biao; Xu, Tianmin; Ji, Fang; Li, Chunyang; Ming, Fang; Zhao, Yun; Cheng, Juan; Chen, Kang; Zhao, Xiang-an; Sang, Dawen; Guan, Xinying; Chen, Xiaobing; Yan, Xiaomin; Zhang, Zhaoping; Liu, Jiacheng; Huang, Rui; Zhu, Chuanwu; Wu, Chao
Title: CaracterÃsticas clÃnicas y pronóstico de los pacientes de COVID-19 con sÃndrome metabólico: un estudio multicéntrico y retrospective Cord-id: exdkyf9k Document date: 2021_6_17
ID: exdkyf9k
Snippet: Background Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge. Methods Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by
Document: Background Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge. Methods Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis. Results Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P=0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P<0.001) and critical illness (4.4% vs. 0.5%, P=0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P<0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P=0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia. Conclusions 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS. Antecedentes Pocos estudios han investigado el impacto del sÃndrome metabólico (SM) en la enfermedad por coronavirus 2019 (COVID-19). Describimos las caracterÃsticas clÃnicas y el pronóstico de los pacientes con COVID-19 confirmados con SM durante la hospitalización y después del alta. Métodos Se incluyeron retrospectivamente 233 pacientes con COVID-19 de los hospitales de 8 ciudades de Jiangsu, China. Se describieron las caracterÃsticas clÃnicas de los pacientes con COVID-19 y se analizaron los factores de riesgo de enfermedad grave mediante un análisis de regresión logÃstica. Resultados Cuarenta y cinco (19,3%) de los 233 pacientes de COVID-19 tenÃan EM. La mediana de edad de los pacientes de COVID-19 con EM fue significativamente mayor que la de los pacientes sin EM (53,0 años frente a 46,0 años, P=0,004). No hubo diferencias significativas en cuanto a los sÃntomas clÃnicos, las imágenes de TC torácica anormales y los fármacos de tratamiento entre los dos grupos. Hubo más pacientes con EM que tuvieron enfermedades graves (33,3% frente a 6,4%, P<0,001) y crÃticas (4,4% frente a 0,5%, P=0,037) que los pacientes sin EM. Las proporciones de insuficiencia respiratoria y sÃndrome de dificultad respiratoria aguda en los pacientes con EM también fueron mayores que en los pacientes sin EM durante la hospitalización. El análisis multivariante mostró que la EM concurrente (odds ratio [OR] 7,668, intervalo de confianza [IC] del 95%: 3,062-19,201, P<0,001) y la linfopenia (OR 3,315, IC del 95%: 1,306-8,411, P=0,012) eran factores de riesgo independientes de enfermedad grave de COVID-19. En una mediana de seguimiento de 28 dÃas tras el alta, se encontró neumonÃa bilateral en el 95,2% de los pacientes con EM, mientras que sólo el 54,7% de los pacientes sin EM presentaron neumonÃa bilateral. Conclusiones El 19,3% de los pacientes con COVID-19 tenÃan EM en nuestro estudio. Los pacientes de COVID-19 con EM son más propensos a desarrollar complicaciones graves y tienen peor pronóstico. Se debe prestar más atención a los pacientes de COVID-19 con EM.
Search related documents:
Co phrase search for related documents- admission measure and logistic regression: 1, 2, 3, 4, 5, 6
- admission measure and logistic regression analysis: 1, 2
- admission measure and lymphocyte count: 1
- logistic regression analysis and long term follow: 1, 2, 3, 4, 5, 6, 7, 8
- logistic regression analysis and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- logistic regression analysis and lower medication: 1, 2
- logistic regression analysis and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- logistic regression analysis and lymphocyte count median wbc: 1
- logistic regression and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- logistic regression and lower medication: 1, 2, 3, 4
- logistic regression and lowering medication: 1
- logistic regression and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- logistic regression and lymphocyte count median wbc: 1
- logistic regression and lymphopenia leukopenia: 1, 2
- long term follow and lopinavir ritonavir: 1
- long term follow and lymphocyte count: 1, 2, 3
- lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lopinavir ritonavir and lymphopenia leukopenia: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date